Can cannabis compounds boost opioid addiction treatment?

NCT ID NCT07148206

Not yet recruiting Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two FDA-approved cannabinoids—dronabinol (synthetic THC) and epidiolex (CBD)—to standard buprenorphine treatment can help people with opioid use disorder stay in treatment and reduce opioid use. The trial will enroll 40 adults who recently started buprenorphine and still have withdrawal symptoms or use other opioids. Participants will take the cannabinoids or placebos for 12 weeks, and researchers will track how many stay in treatment and test positive for buprenorphine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dronabinol (synthetic THC) and Epidiolex (CBD)
What this could lead to: If it works, this could offer a new way to help people early in opioid addiction treatment stay on track and avoid relapse.
What could go wrong: This is a small pilot study with only 40 people, so results may not apply widely. Adding cannabinoids could cause side effects or interact with buprenorphine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Montefiore Health System (Montefiore) Buprenorphine Treatment Network

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.